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A B S T R A C T
Purpose
Patients with Lynch syndrome are at high risk for colon and endometrial cancer, but also at an
elevated risk for other less common cancers. The purpose of this retrospective cohort study was
to provide risk estimates for these less common cancers in proven carriers of pathogenic
mutations in the mismatch repair (MMR) genes MLH1, MSH2, and MSH6.
Patients and Methods
Data were pooled from the German and Dutch national Lynch syndrome registries. Seven different
cancer types were analyzed: stomach, small bowel, urinary bladder, other urothelial, breast,
ovarian, and prostate cancer. Age-, sex- and MMR gene–specific cumulative risks (CRs) were
calculated using the Kaplan-Meier method. Sex-specific incidence rates were compared with
general population incidence rates by calculating standardized incidence ratios (SIRs). Multivariate
Cox regression analysis was used to estimate the impact of sex and mutated gene on cancer risk.
Results
The cohort comprised 2,118 MMR gene mutation carriers (MLH1, n  806; MSH2, n  1,004;
MSH6, n  308). All cancers were significantly more frequent than in the general population. The
highest risks were found for male small bowel cancer (SIR, 251; 95% CI, 177 to 346; CR at 70
years, 12.0; 95% CI, 5.7 to 18.2). Breast cancer showed an SIR of 1.9 (95% CI, 1.4 to 2.4) and a
CR of 14.4 (95% CI, 9.5 to 19.3). MSH2 mutation carriers had a considerably higher risk of
developing urothelial cancer than MLH1 or MSH6 carriers.
Conclusion
The sex- and gene-specific differences of less common cancer risks should be taken into account
in cancer surveillance and prevention programs for patients with Lynch syndrome.
J Clin Oncol 30:4409-4415. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Lynch syndrome (LS), often also termed hereditary
nonpolyposis colorectal cancer (HNPCC), is an
autosomal-dominant inherited disorder caused by
germline mutations in genes of the DNAmismatch
repair (MMR)system.1Patients affectedby this con-
dition are at a considerably increased risk of de-
veloping colorectal and endometrial cancer. In
addition, other cancers such as carcinomas of the
stomach, small bowel, ovaries, biliary tract, urinary
tract, and brain and sebaceous tumors are observed
more frequently than in the general population.2
Reliable estimates of age-, gene-, and sex-specific
risks for these less common cancers are important
for the design of appropriate surveillance and pre-
vention programs. Specific surveillance measures
may be narrowed down and tailored according to
age, sex, and endangered target organ. Moreover,
cancer risksmaybe considerablydifferent according
to the mutated MMR gene, thus making specific
recommendations necessary. Several studies have
been published giving risk estimates for a variety of
extra-colonic, extra-endometrial cancers, including
a large collaborative study combining data of 6,041
provenorprobableMLH1andMSH2mutationcar-
riers from four LS registries.3-13
In this study we aimed to estimate the risks of
less common cancers in patients with a provenmu-
tation in the MMR genesMLH1,MSH2, orMSH6.
Wewereparticularly interested inanalyzing therisks
by sex and mutated MMR gene. Furthermore, we
sought to compare the risk estimates with those
from the general population. To achieve a sufficient
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number of patients for the analysis, the studywas conducted as a joint
project of two registries fromGermany and the Netherlands.
PATIENTS AND METHODS
For thepresent analysis,wepooleddata fromthe registry of theGermanHNPCC
Consortium and the registry of the Netherlands Foundation for the Detection of
HereditaryTumors. TheGerman registry has been collecting data since 1995 and
the Dutch registry since 1986. Details about the two registries are described
elsewhere.13-16 In these two registries, families and patients are ascertained
through clinical criteria based on familial clustering of colorectal cancer or
earlyonsetof cancer (Amsterdamcriteria andBethesdaguidelines).17-20Com-
prehensivedataon the tumor spectrumand the ageofdiagnosiswere collected
for allmembers of the families. The index patients of the families underwent a
standardizedprocess of genetic counseling, tumor tissue analysis formicrosat-
ellite instability and/or immunohistochemical staining ofMMRproteins, and
mutation analysis of the four major MMR genes MLH1, MHS2, MSH6, and
PMS2.PMS2mutationswere toorare tobe included in thepresent analysis.All
participants gave theirwritten informed consent at study inclusion. The ethics
committeesof eachparticipating institutionapproved the study.Acentraldata
quality management process was implemented to ensure high data quality
(automated checks for completeness, plausibility, and consistency), raising
queries in case of errors.
The following information on all mutation carriers were queried from
the two registries: sex, affected MMR gene, age at last follow-up, and year of
birth. For all these individuals, a complete list was generated with all invasive
cancer events, including type of cancer and age at diagnosis (total number of
noncolonic nonendometrial cancers was 389). The present analysis was re-
strictedonly toprovenmutationcarriers. So-calledprobablemutationcarriers
(ie, relatives of a mutation carrier with unknown mutation status but with a
history of colorectal or endometrial cancer) were not included to minimize
biases attributable to potential phenocopies. The group of mutation carriers
comprised the index patients of the families and all relatives who were tested
positive for a pathogenic mutation. Ninety percent of cancer diagnoses were
confirmed bymedical or pathology reports.
Statistical Analysis
Age-dependent cumulative risks (CR) and their 95%CIswere estimated
using the Kaplan-Meier product-limit method. The log-rank test was used to
compare risks between groups (defined by the mutated MMR gene or sex).
Multivariate Cox regression modeling was used to estimate the effect of sex
(only for cancers affecting both sexes) and mutated MMR gene, adjusted by
registry (Germany v Netherlands) and year of birth to account for potential
birth cohort effects. Results were presented as hazard ratios (HR) and their
95% CIs. For each individual, the time under risk reached from birth until
death, last follow-up, or the cancer of interest, whichever came first. For
comparison of risks inmutation carriers with those in the general population,
standardized incidence ratios (SIRs)werecalculatedbydividing thenumberof
observed cases by thenumberof expected cases. Thenumberof expected cases
was calculated bymultiplying the age-, sex-, and annual calender year–specific
incidence rates for the general population with the corresponding person-
years obtained from the study population.Ninety-five percentCIswere calcu-
lated assuming a Poisson distribution. Expected cancer numbers were
calculated separately for the Dutch and German sample using their country-
specific population incidence rates. Incidence rates for the German general
population were obtained from the Saarland Cancer Registry and for the
Dutch general population from the Netherlands Cancer Registry. The earliest
calender year for which incidence data were available was 1970 for Germany
and1989 for theNetherlands. For earlier years,weused linear extrapolationof
incidences from the known calender years.
All reported P values are two-sided. P values .05 were considered
statistically significant. IBM SPSS 20.0.0.1 (SPSS, Chicago, IL) was used for all
data analyses.
RESULTS
The study cohort comprised a total of 2,118 individuals with a
proven pathogenic mutation in MLH1, MSH2, or MSH6. Table 1
shows the basic characteristics. The proportion of male mutation
carriers was significantly higher in the German than in the Dutch
cohort (52.3% v 41.1%, respectively; P  .001), whereas the age
structure was similar (median year of birth, 1957; P  .34). The
distribution of the mutated gene was also significantly different be-
tween the two registries (P  .001). MSH6 mutation carriers were
more frequent in theDutch than in theGermancohort (21.4%v9.9%,
respectively). The frequency of patients with colorectal cancer was
considerably higher in the German than in the Dutch cohort (65.6%
v 26.2%).
Figures 1 and 2 show the age-dependent cumulative risks for the
seven cancer types compared by gene and sex (univariate compari-
son). Table 2 gives information about mean ages at diagnosis, cumu-
lative lifetime risks at 70 years, and SIRs with regard to the general
population. Table 3 summarizes the results of multivariate modeling
of sex andmutated gene, adjusted for registry and year of birth.
Among the seven less common cancer types considered in our
analysis, smallbowelandovariancancer showedtheearliestmeanages
at diagnosis (mean, 46 years for small bowel and 44 years for ovarian
cancer). Only cancers of the stomach, small bowel, and the ovaries
were observed before the age of 30 years. The highest cumulative
lifetime riskswere observed for breast cancer (14.4%; 95%CI, 9.5% to
19.3%) and small bowel cancer in men (12.0%; 95% CI, 5.7% to
18.2%). Stomach cancer in female mutation carriers had the lowest
lifetime risk (2.6%; 95% CI, 1.1% to 4.1%). Clearly significant risk
differences betweenmale and femalemutations carriers could only be
Table 1. Characteristics of the Study Population
Characteristic
Total Germany Netherlands
No. % No. % No. %
All individuals, n 2,118 1,257 861
Sex 1,011 47.7 657 52.3 354 41.1
Male 1,107 52.3 600 47.7 507 58.9
Female
Year of birth
Median 1958 1959 1956
Range 1911-1993 1911-1993 1916-1989
MMR gene
MLH1 806 38.1 483 38.4 323 37.5
MSH2 1,004 47.4 650 51.7 354 41.1
MSH6 308 14.5 124 9.9 184 21.4
Affected with cancer
Colon or rectum 1,050 49.6 824 65.6 226 26.2
Endometrium 177 16.0 102 17.0 75 14.8
Stomach 33 1.6 29 2.3 4 0.5
Small bowel 54 2.5 38 3.0 16 1.9
Urinary bladder 31 1.5 22 1.8 9 1.0
Other urothelium 45 2.1 31 2.5 14 1.6
Breast 50 4.5 26 4.3 24 4.7
Ovary 49 4.4 32 5.3 17 3.4
Prostate 17 1.7 12 2.0 4 1.1
Other cancers 110 5.5 76 6.0 34 3.9
CNS, skin, pancreas, kidney, leukemia, lung, gallbladder, thyroid.
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Fig 1. Age-dependent cumulative risks for (A, B) gastric, (C, D) small bowel, (E, F) urinary bladder, and (G, H) other urothelial cancers, compared by sex (left panels)
and by mutated gene (right panels).
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observedforsmallbowelcancer,withahazardratio(HR)formalecarriers
of 2.52 (95%CI, 1.41 to4.50).Male carriers had a two-fold increased risk
for gastric cancer compared with women (HR 2.00; 95% CI, 0.98 to
4.10); however, this difference was borderline nonsignificant in the
multivariate analysis (P .058). Cancers of the urinary tract showed
no significant risk differences by sex in themultivariate analysis, even
though the risk was estimated to be higher for male carriers.
Risk differences between MLH1, MSH2, and MSH6 mutation
carriers were found for gastric and small bowel cancer, cancers of the
urinary tract (urinary bladder and other urothelial cancers), ovarian
cancer, and prostate cancer. For stomach and small bowel cancer,
MLH1 and MSH2 mutation carriers had similar cumulative risks;
however, MSH6 carriers showed a significantly decreased risk com-
paredwithMLH1 carriers. Regarding urothelial cancer,MSH2muta-
tion carriers had a considerably higher risk comparedwithMLH1 and
MSH6 mutation carriers. A similar gene-dependent risk pattern was
found for prostate cancer, although quantitative risk estimation was
not possible in themultivariate analysis. Adifferent patternwas found
for ovarian cancer, with comparable risks betweenMSH2 andMSH6
mutation carriers and a reduced risk forMLH1mutation carriers.
All seven cancer types were significantly more frequent and oc-
curred earlier than expected in the general population (Table 2). This
was even the case for breast cancer, with an SIR of 1.9 (95%CI, 1.4 to
2.4) andameanageatdiagnosisof 52years (range, 30 to76years).The
highest SIRs were found for small bowel cancer and urothelial cancer
(SIRsbetween100 and251). Therewasno significant heterogeneity in
cancer risks between the German andDutch sample except for stom-
ach cancer, for which the risk was significantly lower in the Dutch


















































































Fig 2. Age-dependent cumulative risks for (A) breast, (B) ovarian and (C)
prostate cancer, compared by mutated gene.
Table 2. Mean Ages at Diagnosis, Cumulative Lifetime Risks, and SIRs
Compared With the General Population
Organ
Male Female
% 95% CI % 95% CI






















Cumulative risk at 70 years
Stomach 6.7 3.1 to 10.3 2.6 1.1 to 4.1
Small bowel 12.0 5.7 to 18.2 3.9 1.2 to 6.5
Urinary bladder 5.5 2.7 to 8.3 3.5 1.4 to 5.5
Other urothelium 9.4 4.6 to 14.1 6.0 2.9 to 9.1
Breast — 14.4 9.5 to 19.3
Ovary — 8.0 5.8 to 10.3
Prostate 9.1 4.4 to 13.8 —
SIR
Stomach 9.8 6.0 to 14.9 7.2 3.7 to 12.6
Small bowel 250.9 176.7 to 345.9 112.2 65.4 to 179.7
Urinary bladder 8.5 5.0 to 13.5 16.2 8.6 to 27.8
Other urothelium 100.4 65.0 to 148.2 121.8 74.4 to 188.2
Breast — 1.9 1.4 to 2.4
Ovary — 13.6 10.0 to 17.9
Prostate 2.5 1.4 to 4.0 —
Abbreviation: SIR, standardized incidence ratio.
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DISCUSSION
In this retrospective cohort study, we investigated the risks of less
common cancers in patients with LS. We were particularly inter-
ested in describing risk differences by sex and mutated MMR gene
(MLH1, MSH2, and MSH6). Colorectal cancer and endometrial
cancer were not included in this analysis because patients were
preferentially ascertained on the basis of the presence of these
cancers in their families. Therefore, in retrospective studies, the
risks for these cancers are likely to be largely overestimated if
the analysis does not account for ascertainment bias.21 Further-
more, we restricted our analysis to individuals with a proven mu-
tation.Many other studies have also included familymemberswith
unknownmutation status. Thesemembers were assumed to have a
mutation if they already had been diagnosed with colorectal or
endometrial cancer (so-called probable mutation carriers). How-
ever, it cannot be excluded that some of these individuals had only
sporadic cancer. Consequently, the inclusion of such individuals
into the analysis may lead on the one hand to an underestimation
of less common cancer risks and on the other hand to an overesti-
mation of colorectal and endometrial cancer risks.
Gastric cancer risk was significantly increased compared with
that of the general population (SIR 9.8 for male and 7.2 for female
mutation carriers). We also found that gastric cancer risk was
considerably lower in the Dutch than in the German study cohort
(HR  0.24). This explains why a separate Dutch study reports
only SIRs of 3.8 formale and 2.7 for female individuals.10However,
the reason for this risk difference remains unclear, especially because
age-standardized incidence rates are not largely different between the
German and Dutch general population.22 Aarnio et al2 reported an
SIRof 6.9 in 360proven andobligatemutation carriers,which ismore
in agreement with our present finding. The cumulative lifetime risks
for gastric cancer inMLH1 andMSH2 carriers in our study were also
in concordance with the figures reported by Watson et al.9 Also in
agreement with the study byWatson et al,9 we did not detect a signif-
icant risk difference for gastric cancer between MLH1 and MSH2
mutation carriers. In contrast to the study ofWatson et al,9 we found
a relevant difference in gastric cancer risk between male and female
individuals (HR 2.00), whichwas significant in the univariate anal-
ysis and nearly significant in the multivariate analysis (P  .02 and
P  .058, respectively). Barrow et al12 also report significant differ-
ences betweenmale and female patients.
Small bowel cancer showed the highest risk increase compared
with the general population (SIR of 251 for male and 112 for female
mutation carriers). Cumulative risk figures at age 70 years are higher
than reported by others.9,12,23 Male carriers had a significantly higher
risk than female carriers (HR  2.5). Small bowel cancer risk was
significantly lower inMSH6mutation carriers compared withMLH1
andMSH2mutation carriers.
Bladder cancer was significantly more frequent than expected in
the general population (SIR of 8.5 formale and 16.2 for femalemuta-
tion carriers). MSH2 mutation carriers had a considerably increased
risk to develop bladder cancer compared with MLH1 and MSH6
carriers.This is inaccordancewith twoother studies,whichalso found
significantly higher risks in MSH2 mutation carriers.7,9 Our result
supports the observation that bladder cancer is part of the tumor
spectrum of LS.
The risk for ovarian cancer was approximately 14 times higher
than in the general population, which is consistent with data from
Aarnioet al.2 Interestingly,MSH2andMSH6 carriershad significantly
higher risks than MLH1 carriers (HR  2.1 for MSH2 and 2.6 for
MSH6, respectively).Watson et al9 have reported previously substan-
tially higher risks for carriers of MSH2 mutations than for MLH1-
mutation carriers.
Our analysis suggests that breast cancer risk is significantly ele-
vated compared with the general population (SIR of 1.9). There was
no significant heterogeneity for breast cancer risk between the Ger-
manand theDutch registry. Therewere alsonodifferences in the risks
betweenMLH1,MSH2, andMSH6.Most other studies didnot showa
significantly higher risk for breast cancer.2,9 However, Scott et al6
reported a significant overrepresentation of breast cancers in MSH2
mutation carriers (SIR  14.77). The lifetime risk for breast cancer
was approximately 14% in our analysis, which is considerably higher
than reported in the studybyWatsonet al9 (5.4%). In the lightof these
conflicting results regarding breast cancer risks, larger studies are
required to further investigate whether breast cancer is part of the
tumor spectrum of LS.
Table 3. Association of Sex and Mutated Gene on the Risks of Less Common
Cancers: Results of Multivariate Cox Regression Modeling
Variable Hazard Ratio 95% CI P
Stomach
Male sex 2.00 0.98 to 4.10 .058
MMR gene
MSH2 1.03 0.52 to 2.06 .936
MSH6   
Small bowel
Male sex 2.52 1.41 to 4.50 .002
MMR gene
MSH2 1.00 0.58 to 1.73 .993
MSH6 0.11 0.02 to 0.83 .032
Urinary bladder
Male sex 1.73 0.84 to 3.54 .137
MMR gene
MSH2 5.42 1.89 to 15.56 .002
MSH6 0.57 0.06 to 5.18 .620
Other urothelium
Male sex 1.54 0.85 to 2.78 .156
MMR gene
MSH2 8.27 2.95 to 23.19  .001
MSH6 1.05 0.19 to 5.78 .957
Breast
MMR gene
MSH2 0.92 0.50 to 1.69 .917
MSH6 0.77 0.34 to 1.76 .539
Ovary
MMR gene
MSH2 2.09 1.04 to 4.21 .040
MSH6 2.59 1.11 to 6.05 .027
Prostate
MMR gene
MSH2   
MSH6   
NOTE. Female sex and MLH1 gene were reference categories adjusted for
registry (Germany v Netherlands) and year of birth.
Abbreviation: MMR, mismatch repair.
No estimation possible.
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The risk of prostate cancer was significantly increased compared
with that of the general population (SIR of 2.5). The highest risk was
found in carriers of MSH2 mutations. Grindedal et al5 recently re-
ported an even higher risk increase for prostate cancer (SIR of 5.9) in
106 mutation carriers. They reported that prostate cancer was only
observed in carriers ofMSH2,MSH6, andPMS2mutations but not in
those withMLH1mutations.
Pancreatic cancerandother typesof cancercouldnotbe included
in our analysis because the number of events was too small to yield
conclusive risk estimates. However, other studies suggest that the risk
ofpancreatic cancer is increased in familieswithLScomparedwith the
general population.4
In our study,male patients with LS generally had higher risks for
gastric, small bowel, and urothelial cancer than female patients. These
risk differences might be explained at least in part by different envi-
ronmental exposures or lifestyles (eg, regarding smoking habits, alco-
hol consumption, or dietary factors).24 Recently, studies have been
published demonstrating an association between smoking or body
mass index and colorectal adenoma or cancer risk.25-28 However,
studies addressing the possible association between these factors and
the less common cancers in LS are not yet available.
Our study confirms that less common cancers show organ-
specific risk differences with regard to the mutated MMR gene. The
reason for this gene and organ specificity is yet not well understood.
TheMMRsystemconsists of differentMMRproteins interactingwith
each other to detect and to repair DNA mismatches. It has been
proposed that likely several distinct mechanisms contribute to the
observed of tissue specificity (eg, cell type–specific mutator targets,
specific apoptotic pathways, interactions between the MMR system
and environmental factors, and others).29
Some limitations of our study should be addressed.PMS2muta-
tioncarrierswerenot included in this study,because theirnumberwas
far too small to obtain reasonable risk estimates. Another limitation is
that retrospective analyses may lead to an overestimation of risks for
those types of cancer, which were the basis for selection (ascertain-
ment bias).21 However, most families were identified by clustering or
early onset of colorectal or endometrial cancer. Therefore, we believe
that risk estimates for the less common noncolonic nonendometrial
cancers should not be severely affected. However, the risk estimates
from our study may not apply to mutation carriers who were ascer-
tained under different conditions and should therefore be interpreted
withcaution.Toovercome the specificproblemofascertainmentbias,
data from prospective studies are required. Ideally, to accumulate
sufficient data in an acceptable time frame, this problem should be
tackled in international collaborative efforts combining data from
largenational registries.Until results fromprospective studiesbecome
available, retrospective analyses must be considered as the best avail-
able basis for clinical decisionmaking.
In summary, there is increasing evidence in the literature that
the risks of less common cancers in LS depend on sex and the
specific mutated MMR gene. These two factors should be taken
into account for specific cancer surveillance strategies. For in-
stance, MSH2 mutation carriers may be included in specific sur-
veillance for urothelial and prostate cancer. In Germany, annual
upper GI endoscopy is currently recommended for all patients
with LS irrespective of the affected MMR gene. However, this
advice could possibly be restricted to patients withMLH1 orMSH2
mutations, as the risk for gastric or small bowel cancer is consider-
ably lower in patients with MSH6 mutations.
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